124 related articles for article (PubMed ID: 34275027)
21. Long non-coding RNA LINC01503 promotes the progression of hepatocellular carcinoma via activating MAPK/ERK pathway.
Wang MR; Fang D; Di MP; Guan JL; Wang G; Liu L; Sheng JQ; Tian DA; Li PY
Int J Med Sci; 2020; 17(9):1224-1234. PubMed ID: 32547318
[No Abstract] [Full Text] [Related]
22. RASSF7 promotes cell proliferation through activating MEK1/2-ERK1/2 signaling pathway in hepatocellular carcinoma.
Zhang M; Li Q; Zhang L; Wang Y; Wang L; Li Q; He T; Wan B; Wang X
Cell Mol Biol (Noisy-le-grand); 2018 Apr; 64(5):73-79. PubMed ID: 29729697
[TBL] [Abstract][Full Text] [Related]
23. Growth arrest-specific gene 2 suppresses hepatocarcinogenesis by intervention of cell cycle and p53-dependent apoptosis.
Zhu RX; Cheng ASL; Chan HLY; Yang DY; Seto WK
World J Gastroenterol; 2019 Aug; 25(32):4715-4726. PubMed ID: 31528096
[TBL] [Abstract][Full Text] [Related]
24. SKA3 Promotes tumor growth by regulating CDK2/P53 phosphorylation in hepatocellular carcinoma.
Hou Y; Wang Z; Huang S; Sun C; Zhao J; Shi J; Li Z; Wang Z; He X; Tam NL; Wu L
Cell Death Dis; 2019 Dec; 10(12):929. PubMed ID: 31804459
[TBL] [Abstract][Full Text] [Related]
25. FBXO17 promotes malignant progression of hepatocellular carcinoma by activating wnt/β-catenin pathway.
Liu FH; Cui YP; He YK; Shu RH
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8265-8273. PubMed ID: 31646557
[TBL] [Abstract][Full Text] [Related]
26. SPAG5 promotes hepatocellular carcinoma progression by downregulating SCARA5 through modifying β-catenin degradation.
Liu H; Hu J; Wei R; Zhou L; Pan H; Zhu H; Huang M; Luo J; Xu W
J Exp Clin Cancer Res; 2018 Sep; 37(1):229. PubMed ID: 30249289
[TBL] [Abstract][Full Text] [Related]
27. CircCCNB1 silencing acting as a miR-106b-5p sponge inhibited GPM6A expression to promote HCC progression by enhancing DYNC1I1 expression and activating the AKT/ERK signaling pathway.
Liu YM; Cao Y; Zhao PS; Wu LY; Lu YM; Wang YL; Zhao JF; Liu XG
Int J Biol Sci; 2022; 18(2):637-651. PubMed ID: 35002514
[No Abstract] [Full Text] [Related]
28. Inhibitory effect of tumor suppressor p33(ING1b) and its synergy with p53 gene in hepatocellular carcinoma.
Zhu Z; Lin J; Qu JH; Feitelson MA; Ni CR; Li FM; Zhu MH
World J Gastroenterol; 2005 Apr; 11(13):1903-9. PubMed ID: 15800978
[TBL] [Abstract][Full Text] [Related]
29. Cell division cycle associated 8: A novel diagnostic and prognostic biomarker for hepatocellular carcinoma.
Cui XH; Peng QJ; Li RZ; Lyu XJ; Zhu CF; Qin XH
J Cell Mol Med; 2021 Dec; 25(24):11097-11112. PubMed ID: 34741389
[TBL] [Abstract][Full Text] [Related]
30. Formiminotransferase Cyclodeaminase Suppresses Hepatocellular Carcinoma by Modulating Cell Apoptosis, DNA Damage, and Phosphatidylinositol 3-Kinases (PI3K)/Akt Signaling Pathway.
Chen J; Chen Z; Huang Z; Yu H; Li Y; Huang W
Med Sci Monit; 2019 Jun; 25():4474-4484. PubMed ID: 31203308
[TBL] [Abstract][Full Text] [Related]
31. Clinical and biological significance of transcription termination factor, RNA polymerase I in human liver hepatocellular carcinoma.
Komatsu H; Iguchi T; Ueda M; Nambara S; Saito T; Hirata H; Sakimura S; Takano Y; Uchi R; Shinden Y; Eguchi H; Masuda T; Sugimachi K; Eguchi H; Doki Y; Mori M; Mimori K
Oncol Rep; 2016 Apr; 35(4):2073-80. PubMed ID: 26821084
[TBL] [Abstract][Full Text] [Related]
32. Upregulation of Stress-Induced Protein Kinase CK1 Delta is associated with a Poor Prognosis for patients with Hepatocellular Carcinoma.
Zhang H; Qiu C; Zeng H; Zhu W; Lyu W; Lao X
Genet Test Mol Biomarkers; 2021 Jul; 25(7):504-514. PubMed ID: 34280005
[No Abstract] [Full Text] [Related]
33. CBX3/HP1γ promotes tumor proliferation and predicts poor survival in hepatocellular carcinoma.
Zhong X; Kan A; Zhang W; Zhou J; Zhang H; Chen J; Tang S
Aging (Albany NY); 2019 Aug; 11(15):5483-5497. PubMed ID: 31375643
[TBL] [Abstract][Full Text] [Related]
34. Downregulation of PRRX1 via the p53-dependent signaling pathway predicts poor prognosis in hepatocellular carcinoma.
Fan M; Shen J; Liu H; Wen Z; Yang J; Yang P; Liu K; Chang Y; Duan J; Lu K
Oncol Rep; 2017 Aug; 38(2):1083-1090. PubMed ID: 28677793
[TBL] [Abstract][Full Text] [Related]
35. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1.
Chen Y; Peng C; Chen J; Chen D; Yang B; He B; Hu W; Zhang Y; Liu H; Dai L; Xie H; Zhou L; Wu J; Zheng S
Mol Cancer; 2019 Aug; 18(1):127. PubMed ID: 31438961
[TBL] [Abstract][Full Text] [Related]
36. Low expression of PIDD is associated with cell proliferation and apoptosis in hepatocellular carcinoma.
Shi W; Huang W; Chen Y; Zhang S; Xu P; Gu X; Fan H; Xu J; Chen Y; Ni R; Lu C; Zhang X
Tumour Biol; 2016 Aug; 37(8):10447-57. PubMed ID: 26846109
[TBL] [Abstract][Full Text] [Related]
37. Circ-ZEB1 promotes PIK3CA expression by silencing miR-199a-3p and affects the proliferation and apoptosis of hepatocellular carcinoma.
Liu W; Zheng L; Zhang R; Hou P; Wang J; Wu L; Li J
Mol Cancer; 2022 Mar; 21(1):72. PubMed ID: 35277182
[TBL] [Abstract][Full Text] [Related]
38. ZMYND8 promotes the growth and metastasis of hepatocellular carcinoma by promoting HK2-mediated glycolysis.
Dou C; Mo H; Chen T; Liu J; Zeng Y; Li S; Guo C; Zhang C
Pathol Res Pract; 2021 Mar; 219():153345. PubMed ID: 33517164
[TBL] [Abstract][Full Text] [Related]
39. NKD1 correlates with a poor prognosis and inhibits cell proliferation by inducing p53 expression in hepatocellular carcinoma.
Zhang S; Li J; Wang X
Tumour Biol; 2016 Oct; 37(10):14059-14067. PubMed ID: 27507614
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU.
Li X; Yu J; Brock MV; Tao Q; Herman JG; Liang P; Guo M
Oncotarget; 2015 May; 6(13):11547-60. PubMed ID: 25909168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
